Biopharma companies can minimise the threat of compulsory licensing by taking strategic steps that benefit both business and patients, says April Abele Isaacson of Kilpatrick Townsend
The globalisation of the biopharma industry has made it increasingly essential for companies to consider parallel patent proceedings across multiple countries, as April Abele Isaacson of Kilpatrick Townsend explains
